Fair and equal access to health care for all is a fundamental principle of the National Health Service (NHS) in England. However, findings from a previous national survey examining the experiences of hearing-impaired patients when accessing services within the primary care setting have revealed that significant barriers continue to exist. The aim of this study was to examine the availability of assistive communication devices for patients with hearing loss at reception desks and in patient waiting areas in hospital outpatient settings. We conducted a cross-sectional telephone survey involving Audiology and Ear, Nose and Throat (ENT) clinics in NHS hospitals in England. Questionnaires were administered to members of staff at clinic reception desks. All NHS hospital trusts in England providing Audiology and ENT services were included in the survey. Information was obtained from a total of 208 individual clinic reception desks. Assistive communication devices were reported to be available at 64 per cent of Audiology (49/76), 42 per cent of ENT (32/76) and 71 per cent of shared Audiology and ENT reception areas (40/56). The most common type of device was an induction loop system. A substantial proportion of survey respondents were not aware of existing facilities. There is a shortage of assistive communication devices in Audiology and ENT clinic reception areas in England. The range of technology currently in place is insufficient. We have identified a significant lack of "deaf awareness" among frontline staff.Implications for rehabilitationProviders of health care services must recognize their legal obligation to ensure that their services are made more accessible to patients with hearing loss.The use of multimodal assistive technology ensures that more patients can benefit.Staff awareness and training is essential in improving the quality of service provision.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/17483107.2019.1604823 | DOI Listing |
Evid Based Dent
January 2025
Public Health Directorate, NHS Lanarkshire, Kirklands, Fallside Road, Bothwell, G71 8BB, UK.
Objectives: To evaluate the use of the Penicillin Allergy Reassessment for Treatment Improvement (PARTI) tool in supporting appropriate penicillin allergy labelling in dental practices.
Design: Parallel mixed methods study.
Methods: Focus groups of patients with documented penicillin allergies and healthcare worker targeted questionnaires were used in gathering feedback on the PARTI tool's design and functionality.
Therapie
December 2024
Centre de biologie et de recherche en santé, pharmacologie, toxicologie et pharmacovigilance, CHU de Limoges, 87042 Limoges, France.
4P medicine (personalized, preventive, predictive, and participatory) is experiencing a remarkable rise, and pharmacogenetics is an essential part of it. However, several obstacles are hindering its deployment. This round table brought together a group of experts to take stock of the situation, reflecting on ways to facilitate the prescription of these tests and the dissemination of the results on a national scale.
View Article and Find Full Text PDFJ Adv Nurs
January 2025
Department of Public Health, University of Stavanger, Faculty of Health Science, Stavanger, Norway.
Aim: To explore patients and nurses' experiences of digital self-management support following participation in a remote patient monitoring intervention.
Design: An exploratory qualitative multimethod study.
Methods: The study was conducted at two Norwegian university hospitals between January 2022 and February 2023.
Nat Cancer
January 2025
Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell carcinoma (mccRCC) has not been well characterized. Here we analyzed pretherapy genomic and transcriptomic data in treatment-naive persons with mccRCC treated with standard-of-care immunotherapies: (1) combination of programmed cell death protein and ligand 1 (PD1/PDL1) and cytotoxic T lymphocyte-associated protein 4 inhibitors (IO/IO) or (2) combination of PD1/PDL1 and vascular endothelial growth factor (VEGF) receptor inhibitors (IO/VEGF).
View Article and Find Full Text PDFBehav Brain Res
January 2025
College of Electronic & Information Engineering, Hebei University, Baoding, China.
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with an unclear pathogenesis to date. Neurofeedback (NFB) had shown therapeutic effects in patients with ASD. In this study,we analyzed the brain functional networks of children with ASD and investigated the impact of NFB targeting the beta rhythm training on these networks.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!